1,384 Shares in Chemed Corporation $CHE Bought by Wilian Securities LLC

Wilian Securities LLC acquired a new stake in Chemed Corporation (NYSE:CHEFree Report) in the fourth quarter, Holdings Channel.com reports. The institutional investor acquired 1,384 shares of the company’s stock, valued at approximately $592,000.

A number of other institutional investors have also recently bought and sold shares of the business. Northwestern Mutual Wealth Management Co. grew its stake in Chemed by 2,444,879.3% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 5,550,103 shares of the company’s stock valued at $2,374,667,000 after purchasing an additional 5,549,876 shares during the period. JPMorgan Chase & Co. grew its stake in Chemed by 122.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 499,968 shares of the company’s stock valued at $223,856,000 after purchasing an additional 275,423 shares during the period. William Blair Investment Management LLC grew its stake in Chemed by 13.6% in the 3rd quarter. William Blair Investment Management LLC now owns 385,124 shares of the company’s stock valued at $172,435,000 after purchasing an additional 46,038 shares during the period. Epoch Investment Partners Inc. grew its stake in Chemed by 29.4% in the 3rd quarter. Epoch Investment Partners Inc. now owns 307,275 shares of the company’s stock valued at $137,579,000 after purchasing an additional 69,878 shares during the period. Finally, TD Asset Management Inc grew its stake in Chemed by 23.1% in the 3rd quarter. TD Asset Management Inc now owns 301,831 shares of the company’s stock valued at $135,142,000 after purchasing an additional 56,546 shares during the period. Institutional investors own 95.85% of the company’s stock.

Insider Activity at Chemed

In other news, CEO Kevin J. Mcnamara sold 2,000 shares of the company’s stock in a transaction on Friday, May 1st. The stock was sold at an average price of $421.13, for a total transaction of $842,260.00. Following the transaction, the chief executive officer owned 90,219 shares of the company’s stock, valued at $37,993,927.47. This represents a 2.17% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 3.33% of the stock is owned by corporate insiders.

Chemed Stock Down 0.0%

Shares of NYSE CHE opened at $441.58 on Friday. Chemed Corporation has a one year low of $365.20 and a one year high of $581.20. The company has a debt-to-equity ratio of 0.11, a current ratio of 0.85 and a quick ratio of 0.83. The business’s fifty day moving average price is $399.53 and its 200-day moving average price is $424.95. The stock has a market capitalization of $5.86 billion, a PE ratio of 24.06, a P/E/G ratio of 1.66 and a beta of 0.54.

Chemed (NYSE:CHEGet Free Report) last issued its quarterly earnings results on Thursday, April 23rd. The company reported $5.65 EPS for the quarter, beating analysts’ consensus estimates of $5.30 by $0.35. Chemed had a return on equity of 27.18% and a net margin of 10.23%.The firm had revenue of $657.51 million for the quarter, compared to analysts’ expectations of $659.22 million. During the same quarter in the prior year, the firm earned $5.63 EPS. The business’s revenue for the quarter was up 1.6% compared to the same quarter last year. Chemed has set its FY 2026 guidance at 24.000-24.75 EPS. On average, equities research analysts anticipate that Chemed Corporation will post 22.3 EPS for the current year.

Chemed Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 16th. Stockholders of record on Thursday, May 28th will be given a dividend of $0.60 per share. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.5%. The ex-dividend date of this dividend is Thursday, May 28th. Chemed’s dividend payout ratio is currently 13.08%.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on CHE. Oppenheimer reduced their price objective on Chemed from $580.00 to $500.00 and set an “outperform” rating for the company in a research note on Friday, February 27th. Zacks Research upgraded Chemed from a “strong sell” rating to a “hold” rating in a research note on Monday, April 27th. Weiss Ratings upgraded Chemed from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Wednesday, April 29th. Royal Bank Of Canada upped their price objective on Chemed from $422.00 to $436.00 and gave the company a “sector perform” rating in a research note on Monday, April 27th. Finally, Wall Street Zen upgraded Chemed from a “hold” rating to a “buy” rating in a research note on Saturday, May 2nd. Two research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $501.50.

Get Our Latest Stock Report on CHE

Chemed Profile

(Free Report)

Chemed Corporation is a diversified provider of essential home services and healthcare solutions in the United States. Headquartered in Cincinnati, Ohio, the company operates through two principal business segments—Roto-Rooter and Vitas Healthcare. Since its founding in 1974, Chemed has built a reputation for reliability and expertise, serving both residential and commercial customers across a broad range of markets.

The Roto-Rooter segment offers a comprehensive suite of plumbing, drain cleaning and water restoration services.

See Also

Want to see what other hedge funds are holding CHE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Chemed Corporation (NYSE:CHEFree Report).

Institutional Ownership by Quarter for Chemed (NYSE:CHE)

Receive News & Ratings for Chemed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed and related companies with MarketBeat.com's FREE daily email newsletter.